Drug intelligence / Profile preview

Vytomo Q100

Development stage: Unknown
Lead developer: Rantomo Lifesciences
Modality: Small Molecules
Administration: Oral

Overview

Vytomo Q100 is a multi-ingredient nutraceutical and dietary supplement developed by Rantomo Lifesciences. Formulated as an oral softgel capsule, it contains a combination of Co-Enzyme Q10 (ubidecarenone), omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid), green tea extract, L-carnitine (levocarnitine), lycopene, multivitamins, and multiminerals. The product is designed for general nutritional supplementation and health support, leveraging the antioxidant properties of its components and the metabolic support provided by vitamins and minerals. It is currently marketed in India for general wellness and nutritional support.

Brand names: Vytomo Q100

Beyond the preview

Go deeper on Vytomo Q100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vytomo Q100.

Explore the full profile